tetano
Editor, Senior Moderator
J Microbiol Immunol Infect
. 2020 May 25;S1684-1182(20)30128-6.
doi: 10.1016/j.jmii.2020.05.014. Online ahead of print.
Lopinavir/ritonavir Use in Covid-19 Infection: Is It Completely Non-Beneficial?
Adewale Bayode Owa[SUP] 1 [/SUP], Olufunke Tolulope Owa[SUP] 2 [/SUP]
Affiliations
Abstract
Covid-19 infection caused by the novel coronavirus SARS-COV-2 continues to be a major global health challenge. Till date, no drug has been approved for the treatment of this infection. A number of medications have been proposed and there are ongoing clinical trials around the world to find a suitable treatment. A recent randomised control trial compared lopinavir/ritonavir with standard care among 199 patients with severe Covid-19 infection and concluded that there was no significant reduction in mortality rate with lopinavir/ritonavir. However, there are a few important lessons which may be learnt from the study apart from the statistical reduction in mortality rate. There was a numerical reduction in mortality rate, less intensive care unit stay and less complications in the lopinavir-ritonavir group. This article points out some of those important lessons with some suggestions for future clinical trials.
Keywords: COVID-19; Lopinavir-ritonavir.
. 2020 May 25;S1684-1182(20)30128-6.
doi: 10.1016/j.jmii.2020.05.014. Online ahead of print.
Lopinavir/ritonavir Use in Covid-19 Infection: Is It Completely Non-Beneficial?
Adewale Bayode Owa[SUP] 1 [/SUP], Olufunke Tolulope Owa[SUP] 2 [/SUP]
Affiliations
- PMID: 32474026
- PMCID: PMC7247474
- DOI: 10.1016/j.jmii.2020.05.014
Abstract
Covid-19 infection caused by the novel coronavirus SARS-COV-2 continues to be a major global health challenge. Till date, no drug has been approved for the treatment of this infection. A number of medications have been proposed and there are ongoing clinical trials around the world to find a suitable treatment. A recent randomised control trial compared lopinavir/ritonavir with standard care among 199 patients with severe Covid-19 infection and concluded that there was no significant reduction in mortality rate with lopinavir/ritonavir. However, there are a few important lessons which may be learnt from the study apart from the statistical reduction in mortality rate. There was a numerical reduction in mortality rate, less intensive care unit stay and less complications in the lopinavir-ritonavir group. This article points out some of those important lessons with some suggestions for future clinical trials.
Keywords: COVID-19; Lopinavir-ritonavir.